SCHEMBL473532

SCHEMBL473532

CC(=O)Oc1ccc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
KDM4E B2RXH2 4/20 0.50
CYP3A4 P08684 2/20 0.50
ABCB11 O95342 1/20 0.50
ACHE P22303 2/20 0.49
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
PKM P14618 1/20 0.47
ALDH1A1 P00352 1/20 0.46
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KMO O15229 1/20 0.46
MEN1 O00255 1/20 0.46
TTR P02766 1/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7161621 0.88 KDM4E (0.56) LMNAKDM4ECYP3A4ACHEPOLB
SCHEMBL6304659 0.84 ACHE (0.59) LMNAKDM4ECYP3A4ACHEPOLB
SCHEMBL1846855 0.84 MCL1 (0.57) LMNAKDM4ECYP3A4ACHEMAPT
SCHEMBL29001439 0.84 KDM4E (0.61) LMNAKDM4ECYP3A4ACHEPOLB
SCHEMBL377507 0.84 CYP3A4 (0.52) LMNAKDM4ECYP3A4ACHEPOLB
SCHEMBL27646258 0.84 CYP3A4 (0.56) LMNAKDM4ECYP3A4ACHEPOLB
SCHEMBL9507367 0.84 KDM4E (0.44) LMNAKDM4EABCB11ALDH1A1KMO
SCHEMBL9255310 0.83 HSP90AA1 (0.48) LMNAKDM4EALDH1A1KMOMEN1
SCHEMBL7001546 0.82 ELANE (0.55) LMNAKDM4EALDH1A1KMOHSP90AA1
SCHEMBL12316409 0.82 LMNA (0.47) LMNAKDM4ECYP3A4ABCB11ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071655-A1 PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5, TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION POXEL (FR) 2012-03-22 US claimed
EP-2411375-A1 PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5 TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION Poxel (FR) 2012-02-01 EP claimed
EP-2161992-B1 ALKOXYLATED ASYMMETRIC ALKYLAMINE SURFACTANTS AS ADJUVANTS AKZO NOBEL NV (NL) 2010-11-17 EP claimed
WO-2010109015-A1 PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5 TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION POXEL (FR) 2010-09-30 WO claimed
EP-2161992-A1 ALKOXYLATED ASYMMETRIC ALKYLAMINE SURFACTANTS AS ADJUVANTS Akzo Nobel N.V. (NL) 2010-03-17 EP claimed
WO-2009004044-A1 ALKOXYLATED ASYMMETRIC ALKYLAMINE SURFACTANTS AS ADJUVANTS AKZO NOBEL N.V. (NL) 2009-01-08 WO claimed
US-4668276-A FOR HERBICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-26 US claimed
CN-120121751-A Method for detecting chlorophenols in waste gas and application thereof 华电莱州发电有限公司 2025-06-10 CN disclosed
EP-4250925-A1 LIQUID AGROCHEMICAL COMPOSITION Nouryon Chemicals International B.V. (NL) 2023-10-04 EP disclosed
CN-112063005-B Preparation method of molecular imprinting integral needle type extraction device for enriching polychlorinated biphenyl 吉林化工学院 2022-12-06 CN disclosed
US-20220324876-A1 4-SUBSTITUTED PYRANO[3,4,b]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY THE ROCKEFELLER UNIVERSITY 2022-10-13 US disclosed
CN-114867350-A Low volatility polyamine salts of anionic pesticides 巴斯夫公司 2022-08-05 CN disclosed
CN-114727597-A Methods of using compositions comprising anionic pesticides and buffers 巴斯夫公司 2022-07-08 CN disclosed
US-4816465-A Decahydroquinolines and analgesic use thereof ROUSSEL UCLAF (FR) 1989-03-28 US disclosed
EP-0162690-B1 2-OXA-SPIROCYCLIC-BENZENEACETAMIDES AND BENZAMIDES THE UPJOHN COMPANY (US) 1989-01-11 EP disclosed
CN-87100191-A The hydroxy acid derivative of treatment diabetic complication 1987-09-09 CN disclosed
WO-1987004344-A1 HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1987-07-30 WO disclosed
EP-0230379-A2 Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications PFIZER INC. (US) 1987-07-29 EP disclosed
US-4588591-A Analgesic 2-oxa-spirocyclic compounds THE UPJOHN COMPANY (US) 1986-05-13 US disclosed
EP-0162690-A2 2-oxa-spirocyclic-benzeneacetamides and benzamides THE UPJOHN COMPANY (US) 1985-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071655-A1 PROCESS FOR ENANTIOMERIC SEPARATION OF RACEMIC DIHYDRO-1,3,5, TRIAZINES VIA PREFERENTIAL CRYSTALLIZATION IRS1, GPR119, INSR LMNA 3711/4885KDM4E 4255/4885CYP3A4 916/4885
US-20220324876-A1 4-SUBSTITUTED PYRANO[3,4,b]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY OPRK1, OPRD1, OPRM1 LMNA 4824/4885KDM4E 1650/4885CYP3A4 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.